13th May 2025

Genedrive® CYP2C19-ID Kit to be used to support expansion of use to include Acute Coronary Syndrome

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to anno...

2nd Apr 2025

Genedrive awarded additional grant funding under the DEVOTE programme

genedrive plc (AIM:GDR), the point of care pharmacogenetic testing company, is pleased to annou...

17th Mar 2025

Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients and MT-RNR1 in newborn babies in NHS Scotland.

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to note...